Bochum, Germany

Ulrich Sonnen-Born

This inventor holds 1 USPTO granted patent. Top assignee: Pharma-Zentral. Active years: 2002.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ulrich Sonnen-Born. Retrieved from https://idiyas.com/inventor/ulrich-sonnen-born

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2002

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Ulrich Sonnen-Born: Innovator in Bacterial Plasmids

Introduction

Ulrich Sonnen-Born is a notable inventor based in Bochum, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of bacterial plasmids.

Latest Patents

Sonnen-Born holds a patent for bacterial plasmids, specifically plasmids pMUT 1 and pMUT 2. These plasmids contain DNA sequences that exhibit significant homologies to replication starting positions of other enterobacterial plasmids. Additionally, the patent discloses expression vectors that incorporate plasmids pMUT 1 and pMUT 2.

Career Highlights

Ulrich Sonnen-Born is associated with Pharma-Zentral, where he continues to advance his research and innovations in biotechnology. His work has implications for various applications in genetic engineering and microbiology.

Collaborations

Sonnen-Born has collaborated with esteemed colleagues, including Jörg Hacker and Jürgen Schulze, contributing to the advancement of their shared research interests.

Conclusion

Ulrich Sonnen-Born's work in bacterial plasmids exemplifies the innovative spirit of modern biotechnology. His contributions are paving the way for future advancements in the field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…